((自动化翻译由路透提供，请见免责声明 ))
1月13日 - ** 制药商Sage Therapeutics 股价盘前上涨36.4%至7.57美元
** 周五提交的一份文件显示，制药公司百健 将以每股7.22美元的价格收购其尚未持有的赛杰公司所有流通股。
** 根据路透的计算，收购价比上周五收盘价高出30%，Sage公司的股权价值为4.417亿美元。
** 经纪公司威廉-布莱尔（William Blair）表示，该收购要约是审慎的，目的是最大限度地挖掘赛捷和百健的抑郁症药物Zurzuvae的潜力，同时不会对百健的并购交易能力产生实质性影响。
** 截至上次收盘，该股在过去12个月中下跌了78.1%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.